Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Evolus, Inc. (EOLS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.91, with a market capitalisation of $523.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.86 to $9.31. This page covers its latest market performance, valuation, price trends and company information.
$523.78M | |
$7.88 | |
$39.50 | |
$2.85 | |
$7.93 | |
464.14K | |
916.19K | |
-- | |
$9.31 | |
$3.86 | |
-- | |
-- |
Evolus, Inc. (EOLS) is trading at $7.84 in pre-market trading as of 2026-09-15 23:31:00, down 1.20% ($0.09) from the previous close of $7.93
Pre-market trading shows how investors are pricing EOLS before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Evolus, Inc. (EOLS) moved from $9.30 to $7.91, representing a decline of 15.00% ($1.40).
The stock traded between $7.59 and $9.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 910.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 74.2%
EOLS is currently trading at $7.91, placing it 74.2% of the way from its 52-week low of $3.86 to its 52-week high of $9.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 353 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Evolus, Inc. (EOLS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.